LLY vs TMDX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
TMDX exhibits a stable financial health profile with a Piotroski F-Score of 4/9 and exceptional liquidity (Current Ratio 7.14). While the Graham Number ($38.85) suggests significant overvaluation from a defensive standpoint, the growth-based intrinsic value of $143.37 indicates the current price of $113.13 is an attractive entry point for growth investors. The company has successfully transitioned from consistent losses to explosive earnings growth and high profitability (ROE 54.24%). Despite bearish insider sentiment and technicals, the fundamental trajectory and analyst consensus remain strongly positive.
Compare Another Pair
Related Comparisons
LLY vs TMDX: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and TransMedics Group, Inc. (TMDX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.